The NINDS Fibroblast, iPSC, and Biomarker Collections are undergoing a minor transition. Please click here for more information.
Overview of PREDICT-HD
PREDICT-HD is a 32-site observational study of individuals at-risk for Huntington's Disease (HD) to collect biospecimens, imaging, and clinical assessments that will help to advance the understanding of the natural history of HD. The goals of the PREDICT-HD study focus on laying the groundwork for future clinical trials in an at-risk HD patient population. The specific aims of the PREDICT-HD study are to: (1) improve prediction of disease diagnosis in healthy individuals using longitudinal measures of plasma, imaging, cognitive function, motor function, and psychiatric state; (2) enable identification of assessment tools for disease progression prior to clinical diagnosis and characterize the natural history of these clinical and/or biological readouts; and (3) improve the validity and reliability of disease measures upon which the power and sensitivity of multi-site trials and studies depend.
The NINDS Repository banks, processes, and distributes biospecimens including plasma, whole blood, and urine collected under the PREDICT-HD study. The NINDS Repository also captures certain clinical data such as gender, diagnosis, CAP group, and age at enrollment. These clinical data are associated with each sample available in the NINDS Repository.
Extensive clinical data including the Unified Huntington's Disease Rating Scale (UHDRS) motor examination, cognitive and neuropsychiatric assessments, and structural MRI imaging have been collected over a ten-year time frame. A subset of these data, representing over 25 clinical variables such as the UHDRS score, CAG repeat length, and Cognitive Assessment Summary (CAS) score, are accessible from dbGaP .
Predict-HD Sample Catalog
Guidelines and Policies